Tech Company Financing Transactions
Bionyra Pharma Funding Round
On 6/22/2026, Bionyra Pharma secured $165 million in Series A funding from Jeito Capital, Sofinnova Partners and Apollo Health Ventures.
Transaction Overview
Company Name
Announced On
6/22/2026
Transaction Type
Venture Equity
Amount
$165,000,000
Round
Series A
Investors
Jeito Capital (Lead Investor)
Sofinnova Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7 Boulevard Haussmann
Paris, 75009
France
Paris, 75009
France
Phone
Undisclosed
Website
Email Address
Overview
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. Bionyra's best-in-class mono and multispecific antibodies target novel immune pathways, enabling deeper and more durable disease control, with an initial focus on atopic dermatitis and inflammatory bowel disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frédéric Marrache
Browse more venture capital transactions:
Prev: 6/22/2026: AppsFlyer venture capital transaction
Next: 6/22/2026: Tugboat Solutions venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs